Ani Pharmaceuticals (ANIP) Price to Sales (2013 - 2026)

Ani Pharmaceuticals has disclosed Price to Sales across 14 years of filings, most recently posting 7.42 for Q2 2026.

• In Q2 2026, Price to Sales rose 7.71% year-over-year to 7.42; the TTM figure through Jun 2026 stood at 2.02 (up 3.56% YoY), while the FY2025 annual figure was 2.01, up 5.82% from the prior year.
• Price to Sales came in at 7.42 for Q2 2026 at Ani Pharmaceuticals, down from 7.69 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 10.75 in Q1 2024 to a low of 6.12 in Q4 2024.
• Average Price to Sales over 5 years is 8.0, with a median of 7.55 recorded in 2022.
• Year-over-year, Price to Sales jumped 60.58% in 2024 and plunged 30.45% in 2025.
• Over 5 years, Price to Sales stood at 7.47 in 2022, then advanced by 16.22% to 8.68 in 2023, then decreased by 29.48% to 6.12 in 2024, then grew by 17.37% to 7.19 in 2025, then grew by 3.28% to 7.42 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 7.42 in Q2 2026, 7.69 in Q1 2026, and 7.19 in Q4 2025.